Genus PLC (GNS) is a publicly traded biotechnology business based in the UK. In the week up to 7 September Genus shares plunged 11.43% to a closing position of 2062p. However, over the last 12 months, Genus's share price has risen by an impressive 74.68% from 2820p. Genus is listed on the London Stock Exchange (LSE). All prices are listed in pence sterling.
Best for
Beginner investments
Best for
0% commission
Best for
Beginners
Best for
Low fees
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 - £9.99 | No minimum | £0.00 £492.60 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £0.00 £492.60 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £8.00 £500.60 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £0.00 £492.60 total |
Capital at risk |
 |
★★★★★ | 0% - 0.25% | £100 | £0.00 £492.60 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £0.00 £492.60 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £11.95 £504.55 total |
Capital at risk |
|
Not yet rated | £0 | No minimum | £1.00 £493.60 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Genus P/E ratio, PEG ratio and EBITDA
Genus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Genus shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Genus's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Genus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £86.9 million.
The EBITDA is a measure of a Genus's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Join 50,000 subscribers who are notified about expert share tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Exelixis? We explain how and compare a range of providers that can give you access to many brands, including Exelixis.
Ever wondered how to buy shares in Five Star Senior Living? We explain how and compare a range of providers that can give you access to many brands, including Five Star Senior Living.
Ever wondered how to buy shares in Community Health Systems? We explain how and compare a range of providers that can give you access to many brands, including Community Health Systems.
Ever wondered how to buy shares in Chiasma? We explain how and compare a range of providers that can give you access to many brands, including Chiasma.
Ever wondered how to buy shares in Healthcare Services Group? We explain how and compare a range of providers that can give you access to many brands, including Healthcare Services Group.
Ever wondered how to buy shares in Catalent? We explain how and compare a range of providers that can give you access to many brands, including Catalent.
Ever wondered how to buy shares in Aytu BioScience? We explain how and compare a range of providers that can give you access to many brands, including Aytu BioScience.
Ever wondered how to buy shares in bluebird bio? We explain how and compare a range of providers that can give you access to many brands, including bluebird bio.
Ever wondered how to buy shares in LHC Group? We explain how and compare a range of providers that can give you access to many brands, including LHC Group.
Ever wondered how to buy shares in Amneal Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Amneal Pharmaceuticals.
